May 15, 2019New England Journal of Medicine823 citationsOpen Access
View Full PaperDabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
Structured PICO
Does dabigatran prevent recurrent stroke compared to aspirin in patients with a recent history of embolic stroke of undetermined source?
P
Population
Patients with a recent history of embolic stroke of undetermined source
I
Intervention
Dabigatran
C
Comparator
Aspirin
O
Outcome
Recurrent strokehard clinical
In patients with a recent embolic stroke of undetermined source, dabigatran was not superior to aspirin for secondary stroke prevention and was associated with more clinically relevant nonmajor bleeding.
Abstract
In patients with a recent history of embolic stroke of undetermined source, dabigatran was not superior to aspirin in preventing recurrent stroke. The incidence of major bleeding was not greater in the dabigatran group than in the aspirin group, but there were more clinically relevant nonmajor bleeding events in the dabigatran group. (Funded by Boehringer Ingelheim; RE-SPECT ESUS ClinicalTrials.gov number, NCT02239120.).